Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market... Show more
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DGIN | 36.79 | 0.72 | +2.01% |
| VanEck Digital India ETF (DGIN) | |||
| DEEF | 39.81 | 0.39 | +0.99% |
| Xtrackers FTSE Developed ex US Multifactor ETF (DEEF) | |||
| FTRB | 24.48 | 0.02 | +0.06% |
| Federated Hermes Total Return Bond ETF (FTRB) | |||
| SCHR | 24.14 | -0.02 | -0.08% |
| Schwab Intermediate-Term US Treasury ETF (SCHR) | |||
| SPMC | 5.70 | -0.14 | -2.40% |
| Sound Point Meridian Capital, Inc. | |||
A.I.dvisor indicates that over the last year, SMTI has been loosely correlated with A. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if SMTI jumps, then A could also see price increases.
| Ticker / NAME | Correlation To SMTI | 1D Price Change % | ||
|---|---|---|---|---|
| SMTI | 100% | -0.19% | ||
| A - SMTI | 47% Loosely correlated | +1.73% | ||
| NTRA - SMTI | 45% Loosely correlated | -14.59% | ||
| MTD - SMTI | 44% Loosely correlated | +2.57% | ||
| TWST - SMTI | 44% Loosely correlated | +0.15% | ||
| IQV - SMTI | 44% Loosely correlated | +2.62% | ||
More | ||||
| Ticker / NAME | Correlation To SMTI | 1D Price Change % |
|---|---|---|
| SMTI | 100% | -0.19% |
| Pharmaceuticals: Other industry (49 stocks) | 32% Poorly correlated | +3.53% |
| Pharmaceuticals industry (152 stocks) | 5% Poorly correlated | +2.52% |
Industry PharmaceuticalsOther
The RSI Oscillator for SMTI moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 30 similar instances when the indicator left oversold territory. In 27 of the 30 cases the stock moved higher. This puts the odds of a move higher at 90%.
Following a +0.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where SMTI advanced for three days, in 186 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
SMTI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 57 cases where SMTI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 84%.
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SMTI as a result. In 59 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.
SMTI moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SMTI crossed bearishly below the 50-day moving average on October 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SMTI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. SMTI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: SMTI's P/B Ratio (36.493) is very high in comparison to the industry average of (4.964). P/E Ratio (-8.481) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (2.050) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (2.777) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SMTI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.